Research in the lurch: August 9, 2017
Rebecca Cooney talks with Representative Barbara Lee and others about the Trump Administration's decision to cancel teen pregnancy prevention research grants midway, without warning (Source: Listen to The Lancet)
Source: Listen to The Lancet - August 9, 2017 Category: General Medicine Authors: The Lancet Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder
On March 15, 2017, FDA announced it is warning that Viberzi (active ingredient eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 22, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about rare but serious allergic reactions with the skin antiseptic chlorhexidine gluconate
On February 2, 2017, the FDA announced it is warning that rare but serious allergic reactions have been reported with the widely used skin antiseptic products containing chlorhexidine gluconate. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 9, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women
On December 14, 2016, FDA is warning that repeated or lengthy use of general anesthetic and sedation drugs during surgeries or procedures in children younger than 3 years or in pregnant women during their third trimester may affect the development of children ’s brains. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 9, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about rare but serious allergic reactions with the skin antiseptic chlorhexidine gluconate
On February 2, 2017, the FDA announced it is warning that rare but serious allergic reactions have been reported with the widely used skin antiseptic products containing chlorhexidine gluconate. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 8, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
The Case Against Fluoroquinolones for Prostate Biopsy
While the FDA and AUA slightly differ on their fluoroquinolone safety warnings for prostate biopsy, Dr Gerald Chodak advises against its use due to the possible severe side effects. (Source: Medscape Urology Podcast)
Source: Medscape Urology Podcast - February 7, 2017 Category: Urology & Nephrology Authors: Medscape Source Type: podcasts
FDA Drug Safety Podcast: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women
On December 14, 2016, FDA is warning that repeated or lengthy use of general anesthetic and sedation drugs during surgeries or procedures in children younger than 3 years or in pregnant women during their third trimester may affect the development of children ’s brains. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - December 28, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Arefa MD's Morning Report: Gastric Bypass, LABAs, New FDA Warning
Dr Arefa Cassoobhoy provides a quick rundown of this week ' s news on long-term effects of gastric bypass surgery, safety of LABAs, and a new black box warning from the FDA. (Source: Medscape Medscape Podcast)
Source: Medscape Medscape Podcast - September 9, 2016 Category: Journals (General) Authors: Medscape Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning
On August 31, 2016, FDA announced that a review has found that the growing use of combining opioid medicines with benzodiazepines and other drugs that depress the central nervous system (CNS) has resulted in serious side effects, including slowed or difficult breathing and deaths. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - September 7, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects
On July 26, 2016, FDA approved changes to the labels of fluoroquinolone antibacterial drugs for systemic use (i.e., taken by mouth or by injection). (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - August 2, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)
On June 14, 2016, FDA strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (brand names Invokana, Invokamet) and dapagliflozin (brand names Farxiga, Xigduo XR). (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 21, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse
On June 7, 2016, FDA is warning that taking higher than recommended doses of the common over-the-counter (OTC) and prescription diarrhea medicine loperamide (brand name Imodium), including through abuse or misuse of the product, can cause serious heart problems that can lead to death. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 15, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
